Instem has announced a positive H1 update, with all three areas of the business performing well in the period with new customer wins in Data Collection and increased volumes in Regulatory Solutions and Informatics. The move towards a SaaS model by both new and existing customers is accelerating, which bodes well for the future. Similarly, there is confirmation that Instem continues to capitalise on the opportunities afforded by the FDA’s SEND standard, with outsourced service revenues more than doubling YoY. Overall trading is described as in line with a positive outlook and we make no change to our forecasts this morning. Instem is one of our Best Ideas for 2019 and is successfully executing on a number of fronts, building strategic value along the way.
